Renub

    United States Liquid Biopsy Market, Size, Forecast 2024-2030, Industry Trends, Growth, Outlook, Insight, Top Companies Analysis

    Excel: 4 Hours
    PDF: 4 Hours
    Sep 2022
    Pages: 180

    United States Liquid Biopsy Market Outlook

    United States Liquid Biopsy Market is expected to reach US$ 803.8 Million by 2027. Liquid biopsy is the molecular examination of nucleic acids, subcellular structures, particularly exosomes, and, in the case of cancer, circulating tumor cells in bodily fluids. Liquid biopsy has been the subject of intense research over the last ten years to develop a less invasive and more precise individualized therapy. Furthermore, due to its sophisticated nature, which includes a short turnaround time and feasibility and the capacity to do early cancer screening, liquid biopsies are becoming more popular in the United States.

     

    united-states-liquid-biopsy-market


    United States Liquid Biopsy Market Size is expected to expand at a CAGR of 17.50% during 2021-2027:

    The liquid biopsy methods are minimally invasive and cost-effective in the United States. As a result, they are a popular alternative for cancer diagnosis among Americans. Other essential driving factors influencing the US liquid biopsy market in the projected period include an increase in patient demand for non-invasive treatment procedures and the number of cancer patients. However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.


    How COVID-19 Affected United States Liquid Biopsy Industry:

    The coronavirus outbreak damaged the US biopsy diagnostics centers, hospitals, supply chains, and clinical trials. As a result, cancer diagnoses were being delayed since clinics had been closed since the start of the COVID-19 pandemic, and diagnosis and screening services were growing slower. In addition, cancer patients had numerous obstacles outside of the pandemic, including increased susceptibility to severe infection and disruptions in treatment or routine medical care. According to our estimates, the United States Liquid Biopsy Market reached US$ 305.4 Million in 2021 post recovery from the pandemic scenario.


    Lung Cancer Accounts for The Dominant Market Share in The Forecast Period:

    The liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer. Lung cancer is expected to have the largest market share during the projection period. According to the American Cancer Society, non-small-cell lung cancer, the most frequent kind of lung cancer in the United States, will be diagnosed in 235,760 persons in 2021. Lung cancer affects one in every 17 men and one in every 15 women at some point in their lives.


    By Product, Assay Kits Holds the Largest Market Share:

    The liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services. Thekits and consumablesare expected to have the most significant market share during the projection period. In the projection period, demand for kits and consumableswill be driven by the ability to repeat sampling for liquid biopsy and their convenience and affordability.


    Circulating Tumor Cells Maintains Their Dominance:

    The liquid biopsy market in the United States is classified into Circulating tumor cells (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs), and Other biomarkers based on the circulating biomarker (cell-free DNA, etc.). Circular tumor cells are expected to maintain their dominance throughout the predicted period. The market demand for Circulating tumor DNA is being driven by the rising frequency of cancer and the introduction of ctDNA-based liquid biopsy analysis, which can evaluate prognosis and tumor progression (ctDNA).


    Other Segment Covered in Our Report Includes the Following:

    • Based on clinical application, the market has been segmented into monitoring, prognosis, theranostics, and screening.
    • In addition, the market has been segmented into blood, urine, and others based on a sample.
    • Finally, based on application, the market has been segmented into molecular health monitoring, therapy selection for other meta cancer, and therapy selection for MBS.
    • The market has been segmented into hospitals and laboratories and government & academic research centers based on end-user.


    Key Companies Insights:

    Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc, and Qiagen are among the important players profiled in our report. These market players in the United States contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.


    Renub Research latest report “United States Liquid Biopsy Market, Forecast By Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and Others), By Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating tumor cell (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs) and Other biomarkers (cell free DNA,etc)), Clinical Application (Monitoring, Prognosis, Theranostics and Screening), Sample (Blood, Urine and Others), Application (Molecular Health Monitoring, Therapy Selection for Other Meta Cancer and Therapy Selection for MBS), End User (Hospitals and Laboratories and Government & Academic Research Centers), Companies (Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc and Qiagen)” provides a detailed analysis of United States Liquid Biopsy Industry.

     

    united-states-liquid-biopsy-market-share


    By Cancer, the Market has been segmented into 5 viewpoints:

    1.    Lung Cancer
    2.    Breast Cancer
    3.    Colorectal Cancer
    4.    Prostate Cancer
    5.    Others


    By Product the Market has been segmented into 3 viewpoints:

    1.    Kits & Consumables
    2.    Instruments
    3.    Services


    By Circulating Biomarkers, the market has been segmented into 4 viewpoints:

    1.    Circulating tumor cell (CTCs)
    2.    Circulating tumor DNA (ctDNA)
    3.    Extracellular vesicles (EVs)
    4.    Other biomarkers (cell free DNA,etc)


    By Clinical Application the market has been segmented into 4 viewpoints:

    1.    Monitoring
    2.    Prognosis
    3.    Theranostics
    4.    Screening


    By Sample the market has been segmented into 3 viewpoints:

    1.    Blood
    2.    Urine
    3.    Others


    By Application, the market has been segmented into 3 viewpoints:

    1.    Molecular Health Monitoring 
    2.    Therapy Selection for Other Meta Cancer
    3.    Therapy Selection for MBS


    By End User, the market has been segmented from 2 viewpoints:

    1.    Hospitals and Laboratories
    2.    Government & Academic Research Centers


    Company Insights:

    •    Overview
    •    Product Portfolio
    •    Financial Insight


    Companies Covered:

    1.    Thermo Fisher Scientific Inc
    2.    Roche Diagnostics
    3.    Bio-Rad Laboratories Inc
    4.    Biocept, Inc.
    5.    Biocartis
    6.    Myriad Genetics, Inc.
    7.    Exact Sciences (Genomic Health)
    8.    NeoGenomics Laboratories
    9.    Quest Diagnostic Inc 
    10.    Qiagen

     

    Report Details:

    Report Features Details
    Base Year 2021
    Historical Period 2016 - 2021
    Forecast Period 2022 - 2027
    Market US$ Million
    Segment Covered Cancer, Product, Circulating Biomarkers, Clinical Application, Application & End User
    Cancer Covered Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and Others
    Companies Covered Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc and Qiagen
    Customization Scope 20% Free Customization
    Post-Sale Analyst Support 1 Year (52 Weeks)
    Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request)


    Frequently Asked Questions:

    1.    How big was United States Liquid Biopsy Market in 2021?
    2.    What is the United States Liquid Biopsy Market growth rate?
    3.    Which segment by application accounted for the largest liquid biopsy market share?
    4.    Who are the key players in the market?
    5.    What are the factors driving the market?
    6.    What has been the COVID-19 impact on the market?

     

    1.    Introduction

    2.    Research & Methodology

    3.    Executive Summary

    4.    Market Dynamics

    4.1    Growth Drivers
    4.2    Challenges


    5.    United States Liquid Biopsy Market

    6.    Market Share – United States Liquid Biopsy

    6.1    By Cancer
    6.2    By Product
    6.3    By Circulating Biomarkers
    6.4    By Clinical Application
    6.6    By Application
    6.7    By End User


    7.    Cancer – United States Liquid Biopsy Market

    7.1    Lung Cancer
    7.2    Breast Cancer
    7.3    Colorectal Cancer
    7.4    Prostate Cancer
    7.6    Others


    8.    Product – United States Liquid Biopsy Market

    8.1    Kits & Consumables
    8.2    Instruments
    8.3    Services


    9.    Circulating Biomarkers – United States Liquid Biopsy Market

    9.1    Circulating tumor cell (CTCs)
    9.2    Circulating tumor DNA (ctDNA)
    9.3    Extracellular vesicles (EVs)
    9.4    Other biomarkers (cell free DNA,etc)


    10.    Clinical Application – United States Liquid Biopsy Market

    10.1    Monitoring
    10.2    Prognosis
    10.3    Theranostics
    10.4    Screening


    11.    Sample – United States Liquid Biopsy Market

    11.1    Blood
    11.2    Urine
    11.3    Others


    12.    Application United States Liquid Biopsy Market

    12.1    Molecular Health Monitoring
    12.2    Therapy Selection for Other Meta Cancer
    12.3    Therapy Selection for MBS


    13.    End User United States Liquid Biopsy Market

    13.1    Hospitals and Laboratories
    13.2    Government & Academic Research Centers


    14.    Company Analysis

    14.1    Thermo Fisher Scientific Inc

    14.1.1    Overview
    14.1.2    Product Portfolio
    14.1.3    Financial Insight

    14.2    Roche Diagnostics

    14.2.1    Overview
    14.2.2    Product Portfolio
    14.2.3    Financial Insight

    14.3    Bio-Rad Laboratories Inc

    14.3.1    Overview
    14.3.2    Product Portfolio
    14.3.3    Financial Insight

    14.4    Biocept, Inc.

    14.4.1    Overview
    14.4.2    Product Portfolio
    14.4.3    Financial Insight

    14.5    Biocartis

    14.5.1    Overview
    14.5.2    Product Portfolio
    14.5.3    Financial Insight

    14.6    Myriad Genetics, Inc

    14.6.1    Overview
    14.6.2    Product Portfolio
    14.6.3    Financial Insight

    14.7    Exact Sciences (Genomic Health)

    14.7.1    Overview
    14.7.2    Product Portfolio
    14.7.3    Financial Insight

    14.8    NeoGenomics Laboratories

    14.8.1    Overview
    14.8.2    Product Portfolio
    14.8.3    Financial Insight

    14.9    Quest Diagnostic Inc

    14.9.1    Overview
    14.9.2    Product Portfolio
    14.9.3    Financial Insight

    14.10    Qiagen

    14.10.1    Overview
    14.10.2    Product Portfolio
    14.10.3    Financial Insight


    List of Figures:

    Figure-01:    United States – Liquid Biopsy Market (Million US$), 2017 – 2021
    Figure-02:    United States – Forecast for Liquid Biopsy Market (Million US$), 2022 – 2027
    Figure-03:    United States – Lung Cancer Market (Million US$), 2017 – 2021
    Figure-04:    United States – Forecast for Lung Cancer Market (Million US$), 2022 – 2027
    Figure-05:    United States – Breast Cancer Market (Million US$), 2017 – 2021
    Figure-06:    United States – Forecast for Breast Cancer Market (Million US$), 2022 – 2027
    Figure-07:    United States – Colorectal Cancer Market (Million US$), 2017 – 2021
    Figure-08:    United States – Forecast for Colorectal Cancer Market (Million US$), 2022 – 2027
    Figure-09:    United States – Prostate Cancer Market (Million US$), 2017 – 2021
    Figure-10:    United States – Forecast for Prostate Cancer Market (Million US$), 2022 – 2027
    Figure-11:    United States – Others Market (Million US$), 2017 – 2021
    Figure-12:    United States – Forecast for Others Market (Million US$), 2022 – 2027
    Figure-13:    Product – Kits & Consumables Market (Million US$), 2017 – 2021
    Figure-14:    Product – Forecast for Kits & Consumables Market (Million US$), 2022 – 2027
    Figure-15:    Product – Instruments Market (Million US$), 2017 – 2021
    Figure-16:    Product – Forecast for Instruments Market (Million US$), 2022 – 2027
    Figure-17:    Product – Services Market (Million US$), 2017 – 2021
    Figure-18:    Product – Forecast for Services Market (Million US$), 2022 – 2027
    Figure-19:    Circulating Biomarkers – Circulating tumor cell (CTCs) Market (Million US$), 2017 – 2021
    Figure-20:    Circulating Biomarkers – Forecast for Circulating tumor cell (CTCs) Market (Million US$), 2022 – 2027
    Figure-21:    Circulating Biomarkers – Circulating tumor DNA (ctDNA) Market (Million US$), 2017 – 2021
    Figure-22:    Circulating Biomarkers – Forecast for Circulating tumor DNA (ctDNA) Market (Million US$), 2022 – 2027
    Figure-23:    Circulating Biomarkers – Extracellular vesicles (EVs) Market (Million US$), 2017 – 2021
    Figure-24:    Circulating Biomarkers – Forecast for Extracellular vesicles (EVs) Market (Million US$), 2022 – 2027
    Figure-25:    Circulating Biomarkers – Other biomarkers (cell free DNA,etc) Market (Million US$), 2017 – 2021
    Figure-26:    Circulating Biomarkers – Forecast for Other biomarkers (cell free DNA,etc) Market (Million US$), 2022 – 2027
    Figure-27:    Clinical Application – Monitoring Market (Million US$), 2017 – 2021
    Figure-28:    Clinical Application – Forecast for Monitoring Market (Million US$), 2022 – 2027
    Figure-29:    Clinical Application – Prognosis Market (Million US$), 2017 – 2021
    Figure-30:    Clinical Application – Forecast for Prognosis Market (Million US$), 2022 – 2027
    Figure-31:    Clinical Application – Theranostics Market (Million US$), 2017 – 2021
    Figure-32:    Clinical Application – Forecast for Theranostics Market (Million US$), 2022 – 2027
    Figure-33:    Clinical Application – Screening Market (Million US$), 2017 – 2021
    Figure-34:    Clinical Application – Forecast for Screening Market (Million US$), 2022 – 2027
    Figure-35:    Sample – Blood Market (Million US$), 2017 – 2021
    Figure-36:    Sample – Forecast for Blood Market (Million US$), 2022 – 2027
    Figure-37:    Sample – Urine Market (Million US$), 2017 – 2021
    Figure-38:    Sample – Forecast for Urine Market (Million US$), 2022 – 2027
    Figure-39:    Sample – Others Market (Million US$), 2017 – 2021
    Figure-40:    Sample – Forecast for Others Market (Million US$), 2022 – 2027
    Figure-41:    Application – Molecular Health Monitoring Market (Million US$), 2017 – 2021
    Figure-42:    Application – Forecast for Molecular Health Monitoring Market (Million US$), 2022 – 2027
    Figure-43:    Application – Therapy Selection for Other Meta Cancer Market (Million US$), 2017 – 2021
    Figure-44:    Application – Forecast for Therapy Selection for Other Meta Cancer Market (Million US$), 2022 – 2027
    Figure-45:    Application – Therapy Selection for MBS Market (Million US$), 2017 – 2021
    Figure-46:    Application – Forecast for Therapy Selection for MBS Market (Million US$), 2022 – 2027
    Figure-47:    End User – Hospitals and Laboratories Market (Million US$), 2017 – 2021
    Figure-48:    End User – Forecast for Hospitals and Laboratories Market (Million US$), 2022 – 2027
    Figure-49:    End User – Government & Academic Research Centers Market (Million US$), 2017 – 2021
    Figure-50:    End User – Forecast for Government & Academic Research Centers Market (Million US$), 2022 – 2027
    Figure-51:    Thermo Fisher Scientific Inc – Global Revenue (Million US$), 2017 – 2021
    Figure-52:    Thermo Fisher Scientific Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-53:    Roche Diagnostics – Global Revenue (Million US$), 2017 – 2021
    Figure-54:    Roche Diagnostics – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-55:    Bio-Rad Laboratories Inc – Global Revenue (Million US$), 2017 – 2021
    Figure-56:    Bio-Rad Laboratories Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-57:    Biocept, Inc. – Global Revenue (Million US$), 2017 – 2021
    Figure-58:    Biocept, Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-59:    Biocartis – Global Revenue (Million US$), 2017 – 2021
    Figure-60:    Biocartis – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-61:    Myriad Genetics, Inc – Global Revenue (Million US$), 2017 – 2021
    Figure-62:    Myriad Genetics, Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-63:    Exact Sciences (Genomic Health) – Global Revenue (Million US$), 2017 – 2021
    Figure-64:    Exact Sciences (Genomic Health) – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-65:    NeoGenomics Laboratories – Global Revenue (Million US$), 2017 – 2021
    Figure-66:    NeoGenomics Laboratories – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-67:    Quest Diagnostic Inc – Global Revenue (Million US$), 2017 – 2021
    Figure-68:    Quest Diagnostic Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
    Figure-69:    Qiagen – Global Revenue (Million US$), 2017 – 2021
    Figure-70:    Qiagen – Forecast for Global Revenue (Million US$), 2022 – 2027


    List of Tables:

    Table-01:    United States – Liquid Biopsy Market Share by Cancer (Percent), 2017 – 2021
    Table-02:    United States – Forecast for Liquid Biopsy Market Share by Cancer (Percent), 2022 – 2027
    Table-03:    United States – Liquid Biopsy Market Share by Product (Percent), 2017 – 2021
    Table-04:    United States – Forecast for Liquid Biopsy Market Share by Product (Percent), 2022 – 2027
    Table-05:    United States – Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2017 – 2021
    Table-06:    United States – Forecast for Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2022 – 2027
    Table-07:    United States – Liquid Biopsy Market Share by Clinical Application (Percent), 2017 – 2021
    Table-08:    United States – Forecast for Liquid Biopsy Market Share by Clinical Application (Percent), 2022 – 2027
    Table-09:    United States – Liquid Biopsy Market Share by Application (Percent), 2017 – 2021
    Table-10:    United States – Forecast for Liquid Biopsy Market Share by Application (Percent), 2022 – 2027
    Table-11:    United States – Liquid Biopsy Market Share by End User (Percent), 2017 – 2021
    Table-12:    United States – Forecast for Liquid Biopsy Market Share by End User (Percent), 2022 – 2027

    • Description
      Price
    • Chapter 8     Pages : 10
      $500
    • Chapter 9     Pages : 14
      $600
    • Chapter 10     Pages : 14
      $600
    • Chapter 11     Pages : 10
      $500
    • Chapter 12     Pages : 10
      $500
    • Chapter 13     Pages : 7
      $400
    • Chapter 14.1     Pages : 5
      $150
    • Chapter 14.2     Pages : 5
      $150
    • Chapter 14.3     Pages : 5
      $150
    • Chapter 14.4     Pages : 5
      $150
    • Chapter 14.5     Pages : 5
      $150
    • Chapter 14.6     Pages : 5
      $150
    • Chapter 14.7     Pages : 5
      $150
    • Chapter 14.8     Pages : 5
      $150
    • Chapter 14.9     Pages : 5
      $150
    • Chapter 14.10     Pages : 5
      $150

    Related Reports